- Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors
-
Thorat A, Jeng LB, Yang HR, Yeh CC, Hsu SC, Chen TH, Poon KS
- KMID: 2397800
- Ann Hepatobiliary Pancreat Surg.
- 2017 Nov;21(4):205-211.
- doi: 10.14701/ahbps.2017.21.4.205
BACKGROUNDS/AIMS: The protective effect of everolimus (EVR) in hepatocellular carcinoma (HCC) patients who receive liver transplantation in terms of reducing the recurrence has not been sufficiently investigated in clinical trials.... -
- CITED
-
- Close
- SHARE
-
- Close
